Welcome to our dedicated page for Wave Life Sciences Ltd. SEC filings (Ticker: WVE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Wave Life Sciences Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Wave Life Sciences Ltd.'s regulatory disclosures and financial reporting.
What the filing shows: The Form 4 reports that Tan Aik Na, a director of Wave Life Sciences (WVE), sold 1,127 ordinary shares on August 5, 2025. The sale was made to cover taxes tied to the vesting of restricted share units and was executed pursuant to a 10b5-1 trading plan at a price of $8.75 per share. After the transaction the reporting person beneficially owned 14,988 shares.
Why the filing exists: This is a standard insider disclosure that records an insider sale made for tax withholding related to equity compensation and documents that the sale followed a prearranged plan.
Event: On August 5, 2025, Wave Life Sciences Ltd. (WVE) filed a Form 8-K disclosing an updated corporate presentation.
Details: The Company stated the presentation, which it uses to "provide updates and summaries of its business," is available in the "For Investors & Media" section of its website at http://ir.wavelifesciences.com/ and is furnished as Exhibit 99.1 to this Current Report. The disclosure is made under Item 7.01 (Regulation FD Disclosure) and expressly notes the presentation is furnished and not "filed" for purposes of Section 18 of the Exchange Act. The exhibits list also includes a Cover Page Interactive Data File (Exhibit 104). No financial statements, earnings data, material transactions, guidance, or additional substantive financial information are included. The report was signed by CFO Kyle Moran on August 5, 2025.
Wave Life Sciences has submitted an Annual Report to Shareholders (ARS) filing with the SEC on June 28, 2025. The document was officially accepted by the SEC on June 23, 2025.
Note: This appears to be a cover page or notice indicating the availability of the full ARS document in PDF format. Without access to the complete PDF document, a detailed analysis of the company's financial performance, operational highlights, and strategic initiatives cannot be provided.
Investors and analysts are advised to access and review the complete PDF document through official SEC channels for comprehensive information about Wave Life Sciences' annual performance, financial position, and future outlook.
Wave Life Sciences Ltd. (“Wave”, Nasdaq: WVE) has released its definitive proxy statement (DEF 14A) for the 2025 Annual General Meeting of Shareholders ("2025 AGM") to be held at 11:30 a.m. ET on 5 August 2025 at 733 Concord Avenue, Cambridge, MA.
The filing asks shareholders to vote on governance, audit, compensation and share-issuance matters:
- Resolutions 1(a)-1(i): Election of nine directors, including CEO Paul B. Bolno and other incumbent board members.
- Resolution 2: Re-appointment of KPMG LLP as independent registered public accounting firm and Singapore auditor for FY 2025, with Audit Committee discretion over remuneration.
- Resolution 3: Approval of the cash and equity-based compensation program for non-employee directors as detailed in the proxy.
- Resolution 4: Amendment of the 2021 Equity Incentive Plan to add 8,000,000 ordinary shares for future awards.
- Resolution 5: Authority under Singapore Companies Act §161 for the Board to allot and issue ordinary shares or convertible instruments until the 2026 AGM.
- Resolution 6 (advisory): “Say-on-pay” vote approving compensation of named executive officers.
- Resolution 7 (advisory): “Say-on-frequency” vote recommending whether say-on-pay should occur every one, two or three years.
No financial results, earnings guidance or major strategic transactions are included; the document is strictly focused on shareholder governance, compensation policy and potential share issuance, elements that may influence dilution levels and board oversight going forward.